Sandra Mihaljevic, Juan Sahuquillo, Raj K. Narayan, Anupama Rani, Shashvat M. Desai, W. Taylor Kimberly, Sudhanshu P. Raikwar, J. Claude Hemphill, Patrick M. Kochanek, Joshua S Catapano, Ruchira M. Jha, Giuseppe Citerio, J. Marc Simard, Ethan Winkler, Kevin N. Sheth, Amanda Munoz-Casabella, Institut Català de la Salut, [Jha RM] Department of Neurology, Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013, USA. Department of Translational Neuroscience, Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013, USA. Department of Neurosurgery, Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013, USA. [Rani A, Raikwar S, Mihaljevic S, Munoz-Casabella A] Department of Translational Neuroscience, Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013, USA. [Desai SM] Department of Neurology, Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013, USA. [Sahuquillo J] Unitat de Recerca en Neurotraumatologia i Neurocirurgia (UNINN), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Recerca en Neurotraumatologia i Neurocirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Jha, R, Rani, A, Desai, S, Raikwar, S, Mihaljevic, S, Munoz-Casabella, A, Kochanek, P, Catapano, J, Winkler, E, Citerio, G, Hemphill, J, Kimberly, W, Narayan, R, Sahuquillo, J, Sheth, K, and Simard, J
Hinchazón celular; Edema; Traumatismo cerebral Cellular swelling; Edema; Traumatic brain injury Inflor cel·lular; Edema; Traumatisme cerebral Sulfonylurea receptor 1 (SUR1) is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) protein superfamily, encoded by Abcc8, and is recognized as a key mediator of central nervous system (CNS) cellular swelling via the transient receptor potential melastatin 4 (TRPM4) channel. Discovered approximately 20 years ago, this channel is normally absent in the CNS but is transcriptionally upregulated after CNS injury. A comprehensive review on the pathophysiology and role of SUR1 in the CNS was published in 2012. Since then, the breadth and depth of understanding of the involvement of this channel in secondary injury has undergone exponential growth: SUR1-TRPM4 inhibition has been shown to decrease cerebral edema and hemorrhage progression in multiple preclinical models as well as in early clinical studies across a range of CNS diseases including ischemic stroke, traumatic brain injury, cardiac arrest, subarachnoid hemorrhage, spinal cord injury, intracerebral hemorrhage, multiple sclerosis, encephalitis, neuromalignancies, pain, liver failure, status epilepticus, retinopathies and HIV-associated neurocognitive disorder. Given these substantial developments, combined with the timeliness of ongoing clinical trials of SUR1 inhibition, now, another decade later, we review advances pertaining to SUR1-TRPM4 pathobiology in this spectrum of CNS disease—providing an overview of the journey from patch-clamp experiments to phase III trials. No funding directly supported the writing of this review. R.M.J. is supported by grants from the National Institute of Neurological Disorders and Stroke (NINDS) (K23NS101036; R01NS115815), and the Barrow Neurological Foundation. J.M.S. is supported by grants from the Department of Veterans Affairs (I01RX003060; 1I01BX004652), the Department of Defense (SC170199), the National Heart, Lung and Blood Institute (R01HL082517) and the NINDS (R01NS102589; R01NS105633).